Pulmonx (Nasdaq:LUNG) announced today that it treated the first patient in a pivotal trial evaluating its AeriSeal system. The CONVERT II trial evaluates AeriSeal in limiting collateral ventilation in severe chronic obstructive pulmonary disease (COPD)/emphysema patients. Pulmonx received a staged FDA investigational device exemption (IDE) to conduct this trial late last year. Collateral ventilation occurs […]
Pulmonx
The 18 most innovative medical devices of 2021
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards. The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition. “The Awards Committee is excited to introduce the nominees for the 2021 […]
Pulmonx back on track for $86M IPO
Pulmonx last week filed a registration statement signaling its intent to raise $86 million in an IPO after withdrawing it earlier this year. Redwood City, Calif.-based Pulmonx filed the $86 million IPO in February but withdrew it in May after raising $66 million in a private financing round. Terms for pricing were not disclosed in […]
The 18 most innovative medical devices of 2020
The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, we are honored […]
Pulmonx raises $66m to commercialize minimally-invasive emphysema treatment
Pulmonx announced today that it raised $66 million in a financing round led by global life science investor Ally Bridge Group. The Redwood City, Calif.-based company also received contributions from new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management and Rock Springs Capital, along with existing investors. Pulmonx secured an additional $17 million in […]
Pulmonx touts new coverage for Zephyr valve
Pulmonx said today that its Zephyr valve designed to treat chronic respiratory disease is now covered by Priority Health under a revised lung volume reduction policy. Redwood City, Calif.-based Pulmonx’s Zephyr valves are designed to provide a less-invasive treatment option for emphysema and chronic obstructive pulmonary disease by blocking off the diseased area of the […]
The 17 most innovative medical devices of 2019
The Galien Foundation recently announced nominees for most innovative medical devices for its 13th Annual Prix Galien USA Awards. The foundation awards the Prix Galien Award annually to examples of outstanding biomedical and technology product achievements that are designed to improve human condition. Nominees need to be FDA approved for market within the last five […]
Pulmonx raises $65m, taps Sung as CFO
Pulmonx said today that it raised $65 million in an oversubscribed equity round and added that it picked up Derrick Sung as its new chief financial officer. Funding in the round was lead by Ally Bridge Group and joined by newly invested RTW Investments, ArrowMark Partners, Driehaus Capital Management and existing investors, the Redwood City, […]
Pulmonx wins Aetna coverage for Zephyr endobronchial valve
Pulmonx said yesterday that it won national coverage through health insurer Aetna for its Zephyr endobronchial valve system intended for treating severe emphysema and chronic obstructive pulmonary disorder. The coverage will make the Zephyr valve available to Aetna’s 22 million members, the Redwood City, Calif.-based company said. Under its new policy, Aetna specifically named the […]
Pulmonx wins FDA approval for Zephyr endobronchial valve
The FDA today granted pre-market approval under its breakthrough devices designation to the Zephyr endobronchial valve made by Pulmonx for treating severe emphysema. Emphysema, a chronic obstructive pulmonary disease, causes irreversible damage to the lung’s alveoli, trapping air during exhalation that in turn can cause the diseased tissue to grow larger and pressure healthy lung tissue. The […]
Pulmonx touts quality of life, lung function improvements in 1-year Zephyr endobronchial valve IDE study
Pulmonx yesterday released one-year results from the pivotal trial of its Zephyr endobronchial valve designed to treat patients with severe emphysema from chronic obstructive pulmonary disease, touting significant improvements in lung function and quality of life. Results from the study were presented at the American Thoracic Society 2018 international conference and published in the American Journal […]
